Clinical trial finds temperature-stable TB vaccine safe, prompts immune response

LOS ANGELES, March 6 (Xinhua) -- A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system, the U.S. National Institutes of Health (NIH) announced on Monday.

The experimental vaccine, named ID93+GLA-SE, was developed by scientists at the Access to Advanced Health Institute in Seattle. It is a recombinant subunit vaccine made from four proteins of Mycobacterium tuberculosis bacteria combined with GLA-SE, an immune-stimulating adjuvant, according to the NIH.